Press releases and official statements

SAKK becomes a partner of SPHN
Press release, June 6, 2024. Available languages:

SAKK Network Trial Award Press release

SAKK Awards 2024 Press release

Sinkende Therapiekosten und reduzierte Nebenwirkungen
Press release, June 6, 2024. Available languages:

Vincent Gruntz is to be the new CEO of SAKK
Press release, May 31, 2024. Available languages:

National Councilor Marianne Binder-Keller and Dr. Christian Rathgeb elected to the SAKK Board
Press release, May 5, 2022. Available languages:

Hans Rudolf Keller is the new CEO of SAKK
Press release, January 27, 2022. Available languages:

Medienmitteilung des Patientenrats der SAKK: NEIN zum Tier- und Menschenversuchsverbot
January 17, 2022. Available languages:

Oasmia Pharmaceutical AB: First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer
Press release, June 10, 2021. Available languages:

Patienten, die in Studien behandelt werden, haben ein besseres Outcome
In Gespräch mit Prof. Dr. med. Roger von Moos.
Download Deutsch.
OncoMag 4/2020.
Download Deutsch.
OncoMag 4/2020.

FAQs on SAKK's financial situation and its restructuring plan

Joint statement on the popular initiative "Yes to the ban on animal and human experiments”
June 4, 2020. Available languages:

Professor Aron Goldhirsch (1946-2020): An exeptional Oncologist, Scientist and Teacher
March 04, 2020. Available languages:

Establishing a SAKK Working Group for Cellular Therapies
Press release, December 12, 2019. Available languages:

SAKK / Celgene «Life Grant» 2019
Press release, November 22, 2019. Available languages:

Kinderspitäler beklagen schwindende Pharmagelder
NZZ am Sonntag, November 17, 2019. Available languages:

Pascal Coullery: Der Forschungsbegriff des Krankenversicherungsgesetzes
Gutachten über die Rechtmässigkeit abgelehnter Kostenübernahme durch die Krankenkassen.
Download Deutsch
Download Deutsch

Lurbinectedin data in Progressive Malignant Pleural Mesothelioma presented at ESMO (SAKK 17/16)
Download english

SAKK / Celgene “HEM Pioneer Grant” 2019 Press Release

Unispitäle steigen in Krebstherapie ein
NZZ am Sonntag, July 28, 2019. Available languages:

Krebs noch zielgerichteter behandeln
Article from April 10, 2019 in Planet Gesundheit

InnoMedica Holding AG: First cancer patient treated with liposomal doxorubicin
Press release, 10 January 2019. Available languages:

Extension of the research network to regional hospitals
Press release, 8 January 2019. Available languages:

SAKK 17/16 Phase II trial of lurbinectedin in progressive mesothelioma
Press release, 17 December 2018. Available languages:

Besser, günstiger, aber unrentabel
Der Bund, 23 November 2018. Available languages:

The 2018 GIST award goes to Dr. med. Michael Montemurro, CHUV, Lausanne and SAKK
Press release, 22 November 2018. Available languages:

Gute Medikamente, böse Pharma
NZZ article, 18 July 2018. Available languages:

InnoMedica bringt erstes Krebsmedikament mit der SAKK in die Schweizer Spitäler
Press release, 2 March 2017. Available languages:

Further strengthening the network of cancer centres in Switzerland
Press release, 1 July 2016. Available languages:

Swiss cancer research network establishes patient representative board
Press release, 3 December 2015. Available languages:

Patientenorientierte klinische Forschung in der Schweiz: 5 prioritäre Handlungsfelder
Fields of action. Available languages: